Motus Gi Holdings (MOTS) AI Stock Analysis

• Market Cap: $6.00
• Dividend Yield: N/A
• Average Volume (3M): 44.53K
• Price to Earnings (P/E): ―
• Beta (1Y): 324.40
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 15
• Sector: Healthcare
• Sector Strength: 52
• Industry: Medical - Devices
• EPS (TTM): -14.95
• Shares Outstanding: 6,388,876
• 10 Day Avg. Volume: 32,400
• 30 Day Avg. Volume: 44,529
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 38 Underperform
• Price Target: ―

Motus Gi Holdings faces significant financial instability with declining revenues, consistent net losses, and negative cash flows. The absence of technical analysis data and a negative P/E ratio suggest continued challenges in market performance and profitability. The lack of earnings call guidance exacerbates uncertainty, leading to a low overall stock score.

Motus Gi Holdings Business Overview & Revenue Model

Company Description

Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.

How the Company Makes Money

Motus GI Holdings generates revenue primarily through the sale and distribution of its Pure-Vu System and related accessories. The company targets hospitals and clinics that perform colonoscopies, promoting the Pure-Vu System as a means to optimize procedure effectiveness and reduce the need for repeat procedures. Revenue is mainly derived from the sales of the system itself, along with ongoing sales of disposable components necessary for each procedure. The company may also engage in strategic partnerships with healthcare providers and institutions to expand its market presence and increase adoption of its technology. Additionally, Motus GI may explore licensing opportunities and collaborative agreements to leverage its technology in broader applications within the gastrointestinal endoscopy market.

Motus Gi Holdings Financial Statement Overview

Summary

Motus Gi Holdings is experiencing severe financial challenges, with declining revenues and consistent net losses. Negative margins and cash flows highlight ongoing financial instability, despite some operational cost management improvements. The balance sheet is moderately leveraged, but ongoing losses risk further equity strain.

Income Statement

The company exhibits a declining revenue trend with a significant decrease from $592,000 in 2022 to $319,000 in 2023. Gross profit margins remain negative, indicating challenges in covering the cost of goods sold. Net profit margins are also severely negative, reflecting continued losses and operational inefficiencies. Although EBIT and EBITDA margins are negative, they show slight improvement compared to previous years, suggesting incremental cost management efforts.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio, which reflects a balanced financial leverage. However, the equity ratio is low, indicating potential risk if liabilities continue to grow. The return on equity is negative due to ongoing losses, highlighting profitability challenges. The company's liquidity position is stable, supported by cash and short-term investments, but overall asset strength is weakening.

Cash Flow

Cash flow analysis shows negative operating and free cash flows. Despite negative free cash flow growth, the company has improved its operating cash flow relative to net income, indicating efforts to manage cash burn. Financing activities provide some relief by bolstering cash reserves, yet reliance on external funding poses a long-term risk.

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	327.00K	319.00K	592.00K	391.00K	98.00K	107.00K
Gross Profit	-160.00K	-250.00K	-204.00K	-233.00K	-398.00K	-29.00K
EBITDA	-9.11M	-11.43M	-16.51M	-17.48M	-18.16M	-23.21M
Net Income	-10.59M	-12.87M	-18.09M	-18.91M	-19.60M	-22.59M
Balance Sheet
Total Assets	7.07M	7.22M	17.65M	26.09M	24.06M	32.26M
Cash, Cash Equivalents and Short-Term Investments	4.94M	4.96M	14.04M	22.56M	20.82M	28.73M
Total Debt	2.44M	2.47M	11.44M	12.08M	8.76M	8.79M
Total Liabilities	4.00M	4.54M	14.67M	16.43M	12.77M	13.93M
Stockholders Equity	3.07M	2.69M	2.98M	9.66M	11.29M	18.33M
Cash Flow
Free Cash Flow	-8.68M	-11.30M	-17.69M	-14.89M	-17.08M	-20.38M
Operating Cash Flow	-8.62M	-11.19M	-17.47M	-14.42M	-16.99M	-19.91M
Investing Cash Flow	-65.00K	-104.00K	-224.00K	-470.00K	8.12M	-5.62M
Financing Cash Flow	4.78M	2.21M	9.17M	16.64M	9.17M	28.02M

Motus Gi Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.95B	-0.40	-42.50%	2.21%	22.29%	-1.85%
HSDT	45 Neutral	$6.40M	―	-344.28%	―	-50.34%	75.15%
VTAK	44 Neutral	$3.03M	―	-179.11%	―	37.61%	68.37%
MOTS	38 Underperform	$6.00	―	-478.86%	―	―	―
BBLG	―	$4.15M	―	-88.80%	―	―	―
IVF	38 Underperform	$3.57M	―	-1294.96%	―	14.74%	-2.42%
BJDX	29 Underperform	$2.17M	―	-96.69%	―	―	98.25%